Updates in the medical management of Parkinson disease

Most, if not all, currently available drugs for Parkinson disease address dopaminergic loss and relieve symptoms. However, their adverse effects can be limiting and they do not address disease progression. Moreover, nonmotor features of Parkinson disease such as depression, dementia, and psychosis are now recognized as important and disabling. A cure remains elusive. However, promising interventions and agents are emerging. As an example, people who exercise regularly are less likely to develop Parkinson disease, and if they develop it, they tend to have slower progression.

[1]  J. Friedman,et al.  Long‐term outcome of clozapine use for psychosis in parkinsonian patients , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  C. Adler,et al.  Efficacy of Rivastigmine for Cognitive Symptoms in Parkinson Disease With Dementia , 2009, The neurologist.

[3]  J. Kane,et al.  Controlled, Double-blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo , 1999 .

[4]  O Rascol A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .

[5]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.

[6]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[7]  A. Lang,et al.  Impulse control disorders in parkinson disease: A multicenter case–control study , 2011, Annals of neurology.

[8]  Parkinson Study Group,et al.  Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients , 1997, Annals of neurology.

[9]  M. Okun,et al.  Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[10]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[11]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[12]  B. Snow,et al.  The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study , 2000, Clinical neuropharmacology.

[13]  G. Deuschl,et al.  Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) , 2002, Acta neurologica Scandinavica.

[14]  W Poewe,et al.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.

[15]  S. Buyske,et al.  A controlled trial of antidepressants in patients with Parkinson disease and depression , 2009, Neurology.

[16]  A. Lees,et al.  Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial , 2001 .

[17]  W. Oertel,et al.  Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[18]  L. Golbe,et al.  Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician , 2001 .

[19]  J. Larsen,et al.  Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations , 1998, Neurology.

[20]  L. Defebvre,et al.  Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[21]  I. McKeith,et al.  SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.

[22]  N P Quinn,et al.  What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[23]  S. Leurgans,et al.  Hallucinations and sleep disorders in PD , 2005, Neurology.

[24]  S. Konitsiotis,et al.  Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.

[25]  F. Stocchi,et al.  Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients , 2004, Journal of Neural Transmission.

[26]  N. Volkow,et al.  Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal , 1994, Synapse.

[27]  Mahlon R DeLong,et al.  Prevalence, etiology, and treatment of depression in Parkinson’s disease , 2003, Biological Psychiatry.

[28]  John G Nutt,et al.  Clinical practice. Diagnosis and initial management of Parkinson's disease. , 2005, The New England journal of medicine.

[29]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[30]  John G. Nutt,et al.  Diagnosis and Initial Management of Parkinson's Disease , 2005 .

[31]  J. Kane,et al.  Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. , 1999, Journal of clinical psychopharmacology.

[32]  D. Brooks,et al.  Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[33]  A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. , 2005, Archives of neurology.